Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease - Insights from randomized clinical trials and human genetics

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Increased plasma apoM levels impair triglyceride turnover in mice

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Circulating cord blood HDL-S1P complex preserves the integrity of the feto-placental vasculature

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Diurnal regulation of sphingolipids in blood

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Lipidomics in biomedical research-practical considerations

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Obesity as a clinical and public health problem: is there a need for a new definition based on lipotoxicity effects?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Hypophosphataemia is common in patients with aneurysmal subarachnoid haemorrhage

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Through seven decades the inverse association between HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease (ASCVD) has been observed in case-control and prospective cohort studies. This robust inverse association fuelled the enthusiasm towards development of HDL cholesterol increasing drugs, exemplified by the cholesteryl ester transfer protein (CETP) inhibitor trials and the extended-release niacin HPS2-THRIVE trial. These HDL cholesterol increasing trials were launched without conclusive evidence from human genetics, and despite discrepant species dependent evidence from animal studies. Evidence from human genetics and from randomized clinical trials over the last 13 years now point in the direction that concentrations of HDL cholesterol, do not appear to be a viable future path to target therapeutically for prevention of ASCVD. A likely explanation for the strong observational association between low HDL cholesterol and high ASCVD risk is the concomitant inverse association between HDL cholesterol and atherogenic triglyceride-rich lipoproteins. The purpose of the present review is to bring HDL cholesterol increasing trials into a human genetics context exemplified by candidate gene studies of key players in HDL biogenesis as well as by HDL cholesterol related genome-wide association studies.

OriginalsprogEngelsk
Artikelnummer159063
TidsskriftBiochimica et Biophysica Acta - Molecular and Cell Biology of Lipids
Vol/bind1867
Udgave nummer1
ISSN1388-1981
DOI
StatusUdgivet - jan. 2022

Bibliografisk note

Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

ID: 69263566